RxDoctor Payments DataLook up a doctor →

Dean Vayser

Podiatrist · Carlsbad, CANPI 1013961598

Payments from drug & device makers

$1,213,720in general payments, 2019–2025

Across 188 payments — averaging $6455.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acera Surgical, Inc.$540K
  • Organogenesis Inc.$288K
  • Biotissue Holdings Inc.$138K
  • Endo Pharmaceuticals Inc.$123K
  • Lexicon Pharmaceuticals, Inc.$55K
  • Averitas Pharma Inc.$23K
  • plus $47K from 17 others
$242,396in research payments, 2019–2025

Across 27 payments — averaging $8977.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Polarityte, Inc.$147K
  • Integra Lifesciences Corporation$94K
  • Lexicon Pharmaceuticals, Inc.$2K

What the payments were for

  • Consulting fees$17,82576%
  • Travel & lodging$2,84012%
  • Food & beverage$2,86512%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,213,720 in reported general payments places this provider in the 95th percentile of 721 podiatrist providers in California.

See all podiatrist providers in California

Medicare billing

Part B allowed, 2024
$111,271
Medicare patients
432
Services billed
1,163

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.16$4,278
Doxycycline Hyclate17$149

Paid to pharmacies, not to this prescriber.

Other podiatrist in Carlsbad

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →